Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against ...

Novo Nordisk’s weekly GLP-1 diabetes drug Ozempic has been included in formularies for patients covered by US private health schemes, and has produced encouraging late-stage trial results in a ...

and have been reaping the rewards of supplying versions of Novo Nordisk's obesity drug Wegovy and Ozempic for diabetes, which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

As we saw in the earlier charts, Novo Nordisk continues to increase its market share in GLP-1-based diabetes treatments, reaching 55.1%—its highest level to date—despite growing competition.